drugset / Trial / NCT00003107
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Treatment
Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients who have hematologic cancer or solid tumor.
Timeline
- Start
- 1997-10
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interleukin-12 | Protein / enzyme biologic | — | — |